关键信息
-
基因名
GUCA1B
- 应用
-
别名
GCAP 2; Guanylate Cyclase Activating Protein Photoreceptor 2; Guanylate cyclase activator 1B; Guanylin 2; Guanylyl cyclase-activating protein 2; GUC1B_HUMAN; GUCA 2; Guca1b
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UMX6
-
表达区间
2-200aa
-
氨基酸序列
GQEFSWEEA EAAGEIDVAE LQEWYKKFVM ECPSGTLFMH EFKRFFKVTD DEEASQYVEG MFRAFDKNGD NTIDFLEYVA ALNLVLRGTL EHKLKWTFKI YDKDGNGCID RLELLNIVEG IYQLKKACRR ELQTEQGQLL TPEEVVDRIF LLVDENGDGQ LSLNEFVEGA RRDKWVMKML QMDMNPSSWL AQQRRKSAMF
-
分子量
23.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
GUCA1B encodes a subunit of the guanylate cyclase activated by calcium and calmodulin, playing a crucial role in phototransduction in retinal photoreceptors. Mutations in the GUCA1B gene have been associated with various retinal degenerative diseases, including retinitis pigmentosa and cone-rod dystrophy, leading to progressive vision loss. Research on GUCA1B recombinant proteins focuses on understanding its functional properties, interactions, and regulatory mechanisms within the phototransduction cascade. By producing and characterizing these recombinant proteins, scientists aim to elucidate how alterations in GUCA1B contribute to retinal pathologies. Furthermore, these studies also seek to explore potential therapeutic approaches, such as gene therapy or pharmacological interventions, that could restore or enhance the function of affected pathways in patients with GUCA1B-related retinal diseases. The investigation of GUCA1B recombinant proteins is pivotal not only for comprehending the underlying molecular mechanisms of sight restoration but also for advancing the development of novel treatments for genetic retinal disorders.
